Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupAggressive LymphomasHodgkin LymphomaIndolent LymphomasDiseaseHodgkin LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, IndolentSubgroupICD10C81.-C83.3MeSHSequenceChemotherapyChemo-substanceCarboplatinDexamethasoneGemcitabineRituximabChemo-substanceCarboplatinDexamethasoneGemcitabineRituximabChemo-substanceCarboplatinDexamethasoneGemcitabineRituximabChemo-substanceCarboplatinDexamethasoneGemcitabineRituximabNo. Substances4 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceBalanced Crystalloid SolutionDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceBalanced Crystalloid SolutionDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneSupportive substanceBalanced Crystalloid SolutionDimetindenFosaprepitantGranisetronParacetamolPegfilgrastimPrednisoloneNo. Substances7Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineTherapy phaseTherapy intentioncurativeRisksAnemia Hb below 8g/dlCardiotoxicityEmetogenicity (MASCC/ESMO)Gastrointestinal ToxicityInfectionsNeurotoxicityNeutropeniaPainThrombocytopenia below 50 000/µl only studiesPublicationAuthorGopal ADiseaserezidivierendes oder refraktäres Non-Hodgkin-Lymphom, ECOG 0-2OriginUniversity of Washington/Fred Hutchinson Cancer Research Center, Seattle, WAProtocols in Revision 1 protocol foundProtocols under revision.R-GDC - Rituximab 375 / Gemcitabine 1000 / Dexamethasone 40 / Carboplatin 5, diffuse large B-non-Hodgkin Lymphoma (PID1681 V1.0)
